Pharma faces complex challenges in rising to ESG scrutiny

In International Investment, Chris Elliott, co-manager of the Evenlode Global Income Fund, and Sawan Kumar, stewardship analyst at Evenlode Investment, discuss the challenges of ESG in the pharmaceuticals industry.

“Improving access to healthcare, creating therapies and vaccines, and driving medicine affordability, while keeping stakeholders happy, is not an easy remit.”

Link

top